GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
663
c/compounding·posted 1 year ago by u/niels_roos

[Meta] the 503B rule is doing its job and people should stop complaining

Explainer Cold Box ×3

the 503B rule is doing its job and people should stop complaining, and here is what changes in practice if it goes ahead.

Asked for potency testing on the finished preparation. They had it. I had assumed they would not.

A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.

The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.

Screenshot none of this. Read the whole thread, including the parts where I am told I am wrong.

947 up / 284 down77% upvoted28 commentsid 1lh3vt9 Aug 2024

28 comments

19 in this archive, depth 4

best — the order this archive was captured in

u/vikram_mbeki68 points·1 year ago

Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.

replysharereportpermalink
u/jonas_eriksen18 points·1 year ago

Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.

replysharereportpermalink
u/bruno_dumitru27 points·1 year ago

the shortage list is the whole legal hinge and people skip it

replysharereportpermalink
u/milos_mensa39 points·1 year ago

Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.

replysharereportpermalink
u/usp_appendixMOD52 points·1 year ago

Added a jurisdiction tag — the answers to this question are completely different in different countries.

replysharereportpermalink
u/ruben_cabrera29 points·1 year ago

What is the beyond-use date and what is it based on?

replysharereportpermalink
u/tove_ogunleye23 points·1 year ago·edited

Is the compound still on the shortage list where you are?

replysharereportpermalink
[deleted]17 points·1 year ago

[deleted]

replysharereportpermalink
u/dario_stanescu18 points·1 year ago

That figure is the starting material purity, not the finished preparation potency. Two different tests.

replysharereportpermalink
u/lina_ndiaye11 points·1 year ago

salt forms are the recurring argument and the answer is boring

replysharereportpermalink
u/hydration_hank8 points·1 year ago

do not assume the concentration matches the branded product

replysharereportpermalink
u/formulary_fighterappeals3 points·1 year ago

Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.

replysharereportpermalink
u/food_noise_gonemaintenance6 points·1 year ago

if a clinic will not name the facility, that is your answer

replysharereportpermalink
u/julia_erdogan7 points·1 year ago

Cosigning the beyond-use date question. What it is based on tells you whether anybody has done stability work.

replysharereportpermalink
u/lift_heavy_thingsresistance training-21 points·1 year ago

potency testing on the finished preparation is the thing to ask for

replysharereportpermalink
u/niels_roosOP23 points·1 year ago

Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.

replysharereportpermalink
u/bruno_dumitru33 points·1 year ago

the pharmacy and the prescriber are two separate questions

replysharereportpermalink
load more comments (2) →
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/compounding

Compounded GLP-1s as a supply route: the 503A/503B distinction, the shortage-list mechanics that made compounding legal and then didn't, state board rules, telehealth prescriber models, and what a compounding pharmacy will and will not tell you about its API source.

53kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/compounding rules
  1. Regulatory claims need a citation to the actual rule, notice or docket.
  2. No pharmacy referral codes. Naming a pharmacy is fine; recruiting for it is not.
  3. API source questions are on-topic and pharmacies dodging them is newsworthy.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.